Cardiorespiratory arrest during the first rituximab infusion in a patient with refractory chronic inflammatory demyelinating polyradiculoneuropathy: a case report
This case report describes a fatal cardiorespiratory arrest occurring during the initial rituximab infusion in a patient with refractory chronic inflammatory demyelinating polyradiculoneuropathy, highlighting the critical need for continuous monitoring and immediate resuscitation capabilities when administering this off-label therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human nervous system relies on a vast network of nerves to carry messages between the brain and the rest of the body. Sometimes, the immune system, which is designed to fight off infections, mistakenly attacks the protective coating of these nerves. This condition, known as chronic inflammatory demyelinating polyradiculoneuropathy, causes muscles to weaken and sensations to fade, making simple tasks like walking or holding objects difficult. For many patients, standard treatments like intravenous immunoglobulin, corticosteroids, and procedures that filter the blood work well. However, a significant group of people does not respond to these therapies or cannot tolerate them. When these standard options fail, doctors sometimes turn to a powerful medication called rituximab. This drug works by targeting and removing specific immune cells that are driving the attack on the nerves. While it offers hope for those with no other choices, the process of giving the drug carries risks, as the body can react violently to the sudden introduction of foreign proteins.
In a recent report, researchers documented a dramatic and dangerous event involving a 69-year-old man with this difficult-to-treat nerve condition. The patient had a history of high blood pressure, an underactive thyroid, and long-term exposure to a common agricultural chemical, though the link between the chemical and his illness remained unclear. After failing to improve with standard immune treatments and suffering a previous cardiac arrest during a blood-filtering procedure, his medical team decided to try rituximab as a last resort. The goal was to stop the immune system from damaging his nerves, but the first attempt to administer the drug led to a life-threatening crisis.
The event unfolded quickly during the initial infusion of the medication. After only about 40 milliliters of the solution had entered the patient's vein, his condition deteriorated abruptly. He experienced sudden trouble breathing and a rapid collapse of his blood pressure. Within moments, his heart stopped beating entirely, entering a state known as asystole, where the heart muscle is completely still. Medical staff immediately began advanced life support, which included intubating the patient to help him breathe and administering strong medications to restart the heart. After ten minutes of intense resuscitation efforts, the patient's heart began beating on its own again. He required a ventilator and temporary support to maintain his blood pressure, but he eventually recovered without further heart problems. The medical team decided to stop the treatment permanently, and the patient was discharged with a plan for follow-up care.
The doctors could not pinpoint the exact biological reason for the heart stopping. They did not test for specific markers in the blood that would confirm an allergic reaction or a massive release of immune signals, so the precise mechanism remains unknown. However, the timing of the event strongly suggests the medication was the cause. The reaction happened almost immediately after the drug was introduced, and no other obvious trigger was present at that moment. The report notes that while the patient had a history of exposure to glyphosate, a common herbicide, scientific evidence does not support a link between low-level occupational exposure and this type of nerve disease, making it unlikely to be the culprit here. Similarly, while the patient had a previous cardiac arrest during a different procedure a year earlier, that event was attributed to metabolic issues and does not explain this specific reaction to the new drug.
This case highlights a critical reality for patients with severe nerve conditions: the first dose of a rescue medication can be the most dangerous. Medical records indicate that the vast majority of fatal reactions to this drug occur during the very first infusion. The reaction can happen within the first few milliliters of the fluid, leaving very little time to intervene. Because the patient's body reacted so severely, the team could not determine if the cause was a classic allergic response, a surge of immune system chemicals, or a mix of both. The absence of a skin rash or swelling, combined with the rapid progression to heart failure, made the specific type of reaction hard to classify without further testing that was not performed.
For patients who cannot tolerate this medication, the report suggests that other options exist, such as a different type of antibody drug that is fully human rather than part animal and part human, which might be less likely to trigger a reaction. However, the safety of switching to these alternatives after such a severe event is not yet fully understood. The primary lesson from this story is that when treating complex patients with powerful drugs, the setting must be prepared for the worst. Continuous monitoring and immediate access to advanced life-saving equipment are not just precautions but necessities, as the body's response can be sudden, severe, and potentially fatal within the first moments of treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.